Support for Indigenous Development of 16-Valent Pneumococcal Vaccine

The Technology Development Board (TDB) of India has provided financial support to TechInvention Lifecare Ltd. for establishing a commercial-scale facility to produce a 16-valent Pneumococcal Conjugate Vaccine (PCV-16). This initiative aims to enhance India's vaccine manufacturing capabilities, reduce reliance on imports, and improve public health by targeting specific pneumococcal serotypes associated with high disease risks. The project is expected to bolster domestic biomanufacturing and support immunization efforts for vulnerable populations.

Source: Original Link

Read more